Regeneron Pharmaceuticals, Inc. (REGN), Sanofi (France) (SAN.PA) Asthma Drug Seen as Potential Game Changer
5/21/2013 7:22:04 AM
More...
|
Multiple Target ALS Drug Ready for Genervon's Phase 2 Trial
5/21/2013 11:30:54 AM
More...
|
Jennerex, Inc. Announces Completion of Enrollment in Phase 2b Clinical Trial of Pexa-Vec for the Treatment of Liver Cancer
5/21/2013 11:16:33 AM
More...
|
TRANSGENE (TRGNY) Announces Completion of Enrollment in TRAVERSE, a Phase 2b Clinical Trial of Pexa-Vec for the Treatment of Liver Cancer
5/21/2013 10:53:02 AM
More...
|
Oncopeptides AB Secures Venture Funding for Phase II Trial of Melflufen in Multiple Myeloma Patients
5/21/2013 10:35:02 AM
More...
|
Ceregene, Inc. Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study
5/21/2013 10:17:28 AM
More...
|
MacroGenics, Inc. Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients With Metastatic Breast Cancer
5/21/2013 10:16:10 AM
More...
|
Verona Pharma Release: Further Clinical Data Highlighting the Significant Bronchodilator Activity of Novel Dual PDE3/4 Inhibitor RPL554 Presented at American Thoracic Society International Conference
5/21/2013 10:04:33 AM
More...
|
Synergy Pharmaceuticals Presents Plecanatide Results From a Large Multicenter Clinical Study at Late-Breaking Abstract Session During Digestive Disease Week 2013
5/21/2013 8:58:21 AM
More...
|
Interleukin Genetics Inc. (ILGN) Announces Positive Initial Results from Ongoing Phase 2a Trial in Chronic Bile Acid Diarrhea
5/20/2013 10:41:27 AM
More...
|
Puma Biotechnology Gains After Rival Drug Data Show No Threat
5/20/2013 7:57:20 AM
More...
|
Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes
5/20/2013 1:52:58 PM
More...
|
Rhythm Announces Study Demonstrating High Prevalence of Diabetic Gastroparesis Symptoms in the U.S.
5/20/2013 1:50:18 PM
More...
|
Synageva BioPharma (GEVA)'s Sebelipase Alfa Receives Breakthrough Therapy Designation for Early Onset LAL Deficiency From the FDA
5/20/2013 10:43:59 AM
More...
|
Cempra Pharmaceuticals, Inc. Presents Post-Phase 2 Analysis of Solithromycin's Efficacy and Safety Results From Patients With Community Acquired Bacterial Pneumonia (CABP)
5/20/2013 10:43:08 AM
More...
|
|